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Abstract
Background: Peptide aptamers are combinatorial protein reagents that bind to targets with a high specificity and
a strong affinity thus providing a molecular tool kit for modulating the function of their targets in vivo.
Results: Here we report the isolation of a peptide aptamer named swiggle that interacts with the very short
(21 amino acid long) intracellular domain of membrane type 1-metalloproteinase (MT1-MMP), a key cell surface
protease involved in numerous and crucial physiological and pathological cellular events. Expression of swiggle in
mammalian cells was found to increase the cell surface expression of MT1-MMP by impairing its internalisation.
Swiggle interacts with the LLY
573 internalisation motif of MT1-MMP intracellular domain, thus disrupting the
interaction with the μ2 subunit of the AP-2 internalisation complex required for endocytosis of the protease.
Interestingly, swiggle-mediated inhibition of MT1-MMP clathrin-mediated internalisation was also found to promote
MT1-MMP-mediated cell migration.
Conclusions: Taken together, our results provide further evidence that peptide aptamers can be used to dissect
molecular events mediated by individual protein domains, in contrast to the pleiotropic effects of RNA interference
techniques.
Background
Peptide aptamers (PAs) are small, artificially engineered
proteins conceptually similar to antibodies [1]. PAs con-
sist of a stable, ideally inert scaffold protein with an
inserted constrained peptide moiety. This in effect pre-
sents a small peptide surface within the tertiary struc-
ture of the scaffold which serv e sa st h eb i n d i n gs i t ef o r
a target protein. In contrast to most of the more than
40 non-antibody scaffolds described to date [2], PAs are
usually isolated by yeast-two hybrid screening of large
libraries of PAs that contain random peptide inserts
against a bait protein of interest. Selection of PAs in
eukaryotic cells in vivo may allow the identification of
interactors that are more easily transferable to mamma-
lian cells than interactors identified using in vitro tech-
niques such as phage-display. PA technology is well
established, with PAs showing biological activity against
a wide variety of proteins from different organisms,
including the human and D. melanogaster Cdk2 proteins
[1,3], the E. coli thymidylate synthase (ThyA) protein
[4], the E6 and E7 proteins from human papilloma virus
(HPV) [5,6], the human EGF receptor [7], and the tran-
scription factors Stat3 [8] and the BCL-6 [9]. Impor-
tantly, some PAs have also been found to block
functions of their target proteins in vivo, such as human
Cdk2 [10], D. melanogaster Cdk1 and 2 [3], E2F [11],
p53 [12], Stat3 [8], Nr-13 [13], and BCL-6 [9].
Membrane-type 1 Matrix Metalloproteinase (MT1-
MMP, also known as MMP-14), is a member of the
large MMP family of enzymes. MT1-MMP plays a
major role in the dynamic remodelling of the extra-cel-
lular matrix (ECM) and has been reported to directly
degrade a broad spectrum of ECM proteins, including
collagen types I, II, and III, fibronectin, laminin 1, lami-
nin 5, fibrin, and aggrecan [14,15]. MT1-MMP has also
been reported to activate proMMP-2 and proMMP-13
[16,17], thereby indirectly increasing its proteolytic
repertoire on or near the cell surface. The protease also
plays a role in the processing of a growing number of
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transglutaminase [19], the integrin aV chain [20] or
syndecan 1 [21] thus modulating cell signalling and the
cellular functions mediated by these molecules.
MT1-MMP has been implicated in a wide spectrum of
physiological and pathological cellular functions [22,23].
MT1-MMP expression, well documented in many
tumours, has been correlated with key in vitro and
in vivo processes of tumour progression including angio-
genesis [24], cell migration and invasion [25], cell
growth [26] and metastatic spread [27,28]. Inhibition or
silencing of the protease has been found to significantly
reduce the invasive phenotype of tumour cells implicat-
ing a leading role for MT1-MMP in such processes
[25,29].
MT1-MMP is a type I transmembrane protein with a
very short intracellular domain (ICD) of just 21 amino
acids. The MT1-MMP ICD has been reported to be
required for cell migration and invasion [30-33] as well
as tumour growth [34]. The identification of proteins
interacting with the MT1-MMP ICD, such as MTCBP-1
[35], and glCqR [36] have also helped in defining new
localisations and cellular functions for this protease. The
MT1-MMP ICD has also been implicated in the interna-
lisation [31] and the recycling of the protease to the cell
surface [37]. Consistent with this, MT1-MMP ICD has
been reported to interact with the μ2 subunit of the
AP-2 complex [31] as well as with caveolin-1 [38]
To date, crucial information on the cellular function
of the intracellular domain of the protease has been
obtained following exogenous expression of mutant
MT1-MMP ICD constructs [31,32,39,38,37,40,41,33] or
constructs with a partially or completely deleted ICD
[30,42,26,43,40,34]. In order to assess the role of the
MT1-MMP ICD without using exogenously truncated
or mutated forms of the protease, we decided to make
use of PA technology.
In this study, we identify and characterize a PA, named
swiggle, which interacts with the 21 amino acid ICD of
MT1-MMP. Expression of swiggle in human cells was
found to stimulate MT1-MMP mediated cell migration.
Detailed analysis of the phenotypic effect of swiggle
revealed that the PA inhibits internalization of MT1-
MMP resulting in the accumulation of the protease at
the cell surface. Our data indicate that swiggle interacts
with the LLY
573 motif in the MT1-MMP ICD and com-
petes with the μ2 subunit of the AP-2 complex in cells,
thereby inhibiting the endocytosis of MT1-MMP.
Results
Isolation of peptide aptamers that interact with the
MT1-MMP ICD
In order to identify PAs that interact with the MT1-
MMP ICD, a yeast two-hybrid screen was performed as
previously described [1]. The 21 amino acid ICD of
MT1-MMP was fused to the LexA DNA-binding
domain (DBD) to generate the bait (LexA-MT1). As
prey constructs, we used a library of 10
6 unique 10-
amino acid residue peptides that were inserted into the
active loop of the E. coli thioredoxin (TrxA) scaffold
protein. The prey constructs were transformed into the
EGY42 yeast strain, which was then mated with EGY48
cells expressing LexA-MT1. Replica plating of the
resulting diploids to selective media gave rise to 78 colo-
nies where the LEU2 reporter gene was activated. From
these, only two plasmids were isolated that, when
re-transformed into fresh EGY42 cells, still led to the
activation of the LEU2 and LacZ reporter genes in the
presence of LexA-MT1. These two PAs were named
swiggle and 76. Sequence analysis revealed that, as
expected, swiggle comprises a 10 amino acid peptide
within TrxA (Figure 1A). PA 76 was found to comprise
a 25 amino acid sequence carboxy-terminal to the active
loop of TrxA (Figure 1A). Peptides longer than 10 resi-
dues arise when two or more peptide-encoding oligonu-
cleotides ligate to each other during library
construction. In this case, the 3’ of the fused oligonu-
cleotide encodes an in-frame stop codon. In contrast to
swiggle, PA 76 is not constrained (in 2 dimensions) at
the carboxy-terminus and can be described as a linear
peptide fused to the carboxy-terminus of a truncated
TrxA fragment (Figure 1A), although it is possible that
residues in this “peptide” form ionic or hydrophobic
interactions with expressed regions of the TrxA scaffold,
leading to at least some element of three-dimensional
constraint. Blast searches of Genbank with each PA
insert sequence revealed no similarity with known
proteins.
To confirm the interaction of the selected PAs with
MT1-MMP ICD, yeast interaction mating experiments
were performed [44]. Haploid yeast strains expressing
the LexA DNA-binding domain alone (LexA-DBD),
LexA DBD fusions to the MT1-MMP ICD (LexA-MT1)
or Cdk4 (LexA-Cdk4) were mated with strains expres-
sing B42 activation domain (AD) fusions to TrxA (AD-
TrxA), swiggle (AD-swiggle), 76 (AD-76) or Cyclin D1
(AD-CyclinD1). We included in this assay a fusion of
the AD to a mutant variant of swiggle, called s14, identi-
fied by random mutagenesis, which no longer binds to
the LexA-MT1 fusion protein. s14 differs from swiggle
by a single amino acid: GGLIPCYFMH in swiggle to
GGLIPCYFTH in s14 (Figure 1A). Resulting diploids
were grown on selective media to identify positive (Fig-
ure 1B, grey squares) or negative (Figure 1B, white
squares) interactions. As expected, a clear interaction
was observed between the LexA-Cdk4 and AD-CyclinD1
pair used as a positive control (Figure 1B). LexA-MT1
did not bind to AD-TrxA, AD-s14 or AD-CyclinD1 but
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1B) could be observed confirming that both PAs inter-
act, via the inserted peptide, with the MT1-MMP ICD.
In some experiments, a weak interaction between the
LexA-DBD and AD-76 could also be observed, suggest-
ing that PA 76 may also recognize sequences or surfaces
from the LexA-DBD (data not shown). No interaction
was detected between the LexA-DBD and AD-TrxA,
AD-swiggle, AD-s14, AD-76 or AD-CyclinD1 (Figure
1B). AD-swiggle was also found to interact with the ICD
of MT2-MMP and MT3-MMP (LexA-MT2 and -MT3
in Figure 1B). AD-76 clearly interacted with LexA-MT3
and a weak interaction with LexA-MT2 was observed.
AD-swiggle and AD-76 did not interact with the ICD of
MT5-MMP (LexA-MT5 in Figure 1B). Taken together,
our data clearly demonstrate an interaction between the
MT1-MMP ICD and both PAs. The weak interaction
between AD-76 and LexA-DBD, coupled with the trun-
cated structure of PA 76 and its instability when
expressed in E. coli and mammalian cells (data not
shown) led us to focus on swiggle in subsequent
experiments.
Figure 1 Isolation and validation of PAs interacting with MT1-MMP ICD. (A) Schematic representation of the TrxA scaffold and the PAs
swiggle, 76, and s14. The sequences of the peptide inserted in TrxA (swiggle, s14) or fused to the N-terminal region of TrxA (76) are detailed.
The point mutation in the sequence of s14 is depicted in bold and the amino acids in lower cases in PA 76 represent linkers between the
multiple peptides. * denotes the stop codon. (B) Swiggle interacts with the MT1-MMP ICD in a yeast-two hybrid interaction assay. EGY48 cells
expressing LexA-DBD, LexA-MT1, LexA-MT2, LexA-MT3, LexA-MT5 or LexA-Cdk4 were mated with EGY42 cells expressing AD-TrxA, AD-swiggle,
AD-s14, AD-76 or AD-CyclinD1 and plated onto selective media.
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MCF7 cells
These interactions between swiggle and the MT1-MMP
ICD led us to test whether the two proteins could also
interact when co-expressed in mammalian cells. TrxA-
based PAs have previously been reported to be occa-
sionally difficult to express in mammalian cells [45].
This was also the case for swiggle with poor expression
observed in all the cell lines tested (data not shown).
Increased swiggle stability and improved detection by
western blot were achieved by fusing GFP to the amino
terminus of the PA (Figure 2A). Addition of the tag also
allowed detection of the PA by fluorescence microscopy.
GFP was also added to the amino terminus of TrxA and
s14 to generate GFP-TrxA and GFP-s14, respectively.
We used the human MCF7 breast carcinoma cells,
which do not naturally express MT1-MMP [46]. mRNA
expression for MT2- and MT3-MMP in these cells is
very low (our unpublished data and [26]). MCF7 cells
were co-transfected with MT1-MMP, and either GFP-
swiggle or GFP-TrxA. Total cell lysates were subjected
to immunoprecipitation with an anti-GFP antibody fol-
lowed by Western blot analysis with an anti-MT1-MMP
antibody (Figure 2B). No MT1-MMP was found asso-
ciated with the immunoprecipitates when the anti-GFP
antibody was omitted (Figure 2B, lanes 1 and 2, top
panel) eliminating the possibility of non-specific binding
of the GFP-tagged constructs or MT1-MMP to the
beads. MT1-MMP was clearly found to co-immunopre-
cipitate with GFP-swiggle (Figure 2B, lane 4, top panel
and Figure 2C, lane 4, bottom panel), but not with GFP-
TrxA (Figure 2B, lane 3, top panel) or GFP-s14 (Figure
2C, lane 3, bottom panel). Together our data demon-
strate that swiggle can recognise and interact with the
MT1-MMP ICD within human cells.
GFP-swiggle increases MT1-MMP-mediated cell migration
The interaction between the intracellular domain of
MT1-MMP and swiggle in human cells led us to ask
whether we could detect functional effects of the PA on
an ICD-mediated cellular function of the protease. The
MT1-MMP ICD has previously been reported to play an
important role in promoting cell migration [42,39]. In
order to test whether swiggle could alter ICD-dependent
MT1-MMP-mediated cell migration, we performed a
cell migration assay [18,31,47,33]. Untransfected MCF7
cells as well as cells expressing MT1-MMP alone, MT1-
MMP and either GFP-s14 or GFP-swiggle were plated
on colloidal gold-coated coverslips. After 24 hours incu-
bation at 37°C, the areas of the phagokinetic tracks gen-
erated by cell migration were measured. As expected,
very little migration was observed for untransfected
MCF7 cells (Figure 3A). Expression of MT1-MMP alone
resulted in increased (3 fold in our case) cell migration
compared to untransfected cells (Figure 3A) as pre-
viously observed [39,42,48]. To our surprise, expression
of MT1-MMP and GFP-swiggle (Figures 3A and 3C)
resulted in a considerable increase (5.5 fold) in cell
migration compared to cells expressing MT1-MMP
alone (Figure 3C). Expression of GFP-s14 did not have
any effect on MT1-MMP-mediated cell migration (Fig-
ures 3A and 3C). All told, cells co-expressing MT1-
MMP and swiggle showed a 15-fold enhancement in
migration compared to untransfected MCF7 cells.
Together, these observations indicate that expression of
GFP-swiggle can affect a cellular function of the intra-
cellular domain of MT1-MMP.
GFP-swiggle increases expression of MT1-MMP at the cell
surface
Another observed role for the ICD is the internalisation
of MT1-MMP from the plasma membrane [31,32,49].
The amplification of MT1-MMP-mediated cell migra-
tion observed after expression of GFP-swiggle could
therefore be the result of an increased expression of the
protease at the cell surface. To test this hypothesis, total
exposed cell surface proteins of MCF7 cells over-expres-
sing MT1-MMP, and either GFP, GFP-TrxA, GFP-s14
or GFP-swiggle were biotinylated and immunoprecipi-
tated using an anti-biotin antibody. The presence of
MT1-MMP was then detected in the complexes by
immunoblotting. Inspection of total cell lysates indicated
that the absolute levels of MT1-MMP were unaffected
by co-expression of any of the GFP fusions. Of this cel-
lular pool, a similar amount of MT1-MMP was detected
at the cell surface of MCF7 cells co-expressing GFP
(Figure 4, lane 1), GFP-TrxA (Figure 4, lane 2) or GFP-
s14 (Figure 4, lane 3). In contrast, the cell surface
expression of the protease was clearly increased when
GFP-swiggle was co-expressed with MT1-MMP (Figure
4, lane 4).
The activity of cell-surface localised MT1-MMP can
be assessed using a Texas Red-labelled gelatin (TR-gela-
tin) degradation assay [50]. MCF7 cells transfected with
expression constructs for either MT1-MMP, a catalyti-
cally inactive MT1-MMP E240A mutant or an ICD-
deleted MT1-MMP (MT1-MMP ΔICD) together with
either GFP-swiggle or GFP-s14 were plated onto TR-
gelatin coated slides and incubated at 37°C. As expected,
untransfected MCF7 cells or cells expressing the cataly-
tically inactive MT1-MMP E240A mutant were unable
to degrade the TR-gelatin and this result was unaffected
by co-expression of either GFP-s14 or GFP-swiggle (Fig-
u r e5 C ) .E x p r e s s i o no fa c t i v eM T 1 - M M Pa l o n ei n
MCF7 cells resulted in a clear degradation of the TR-
gelatin (Figure 5C) as previously observed in CHO-K1
and CHO L761 cells expressing the protease [50,51]. A
similar level of TR-gelatin degradation was also observed
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5A and 5C). In contrast, expression of MT1-MMP
together with GFP-swiggle resulted in a 2.5 fold increase
in the average area of TR-gelatin degradation per cell
(Figures 5B and 5C) compared to MCF7 cells expressing
MT1-MMP alone or together with GFP-s-14 (Figure
5C). Increased TR-gelatin degradation was not observed
in MCF7 cells expressing an active MT1-MMP with a
deleted ICD (MT1-MMP ΔICD) [52] or in cells
co-expressing MT1-MMP ΔICD and GFP-swiggle or
GFP-s14 (Figure 5C). Together, these data show that
GFP-swiggle is able to increase the levels of MT1-MMP
activity at the cell surface through interaction with the
MT1-MMP ICD. Consistent with the increased level of
Figure 2 GFP-swiggle co-immunoprecipitates with MT1-MMP. (A) Western blot analysis of protein extracts prepared from MCF7 expressing
GFP (lane 1), GFP-TrxA (lane 2), GFP-s14 (lane 3) or GFP-swiggle (lane 4) using an anti-GFP polyclonal serum. (B) Cell lysates prepared from MCF7
cells expressing MT1-MMP and GFP-TrxA (lanes 1 and 3), MT1-MMP and GFP-swiggle (lanes 2 and 4) were immunoprecipitated with an anti-GFP
polyclonal antibody (lanes 3 and 4). The presence of MT1-MMP (top panel) and GFP-TRxA and GFP-swiggle (middle panel) in the
immunocomplexes was monitored by Western blotting. The expression level of MT1-MMP in the input lysates was analysed by Western blot
(bottom panel). (C) Cell lysates from MCF7 cells expressing MT1-MMP (lanes 1 and 2), MT1-MMP and GFP-s14 (lanes 3 and 5), MT1-MMP and
GFP-swiggle (lanes 4 and 6) were immunoprecipitated with an anti-MT1-MMP pAb (lanes 1, 3 and 4). MT1-MMP, GFP-s14 or GFP-swiggle were
detected in the input lysates (lanes 2, 5 and 6) and immunoprecipitated materials (lanes 1, 3 and 4) using an anti-MT1-MMP pAb or an anti-GFP
polyclonal serum, respectively.
Wickramasinghe et al. BMC Cell Biology 2010, 11:58
http://www.biomedcentral.com/1471-2121/11/58
Page 5 of 15MT1-MMP protein at the surface of cells expressing
GFP-swiggle, these data also confirm that the increase
of the protease at the cell surface is mediated by the
interaction between GFP-swiggle and the ICD of MT1-
MMP.
Swiggle inhibits MT1-MMP internalization
The simplest explanation for the swiggle- and ICD-
mediated increased expression of MT1-MMP at the cell
surface is that GFP-swiggle expression results in a per-
turbation of the internalization of the protease [49,31].
We tested whether expression of GFP-swiggle could
interfere with the internalization of the protease by per-
forming an antibody internalization assay using the
N175 anti-MT1-MMP pAb. This antibody is directed
against the whole extracellular domain of the protease
and recognises full length as well as the 45 kDa inactive
form of the protease [49,50]. MCF7 cells expressing
Figure 3 GFP-swiggle increases MT1-MMP mediated cell migration. (A) Untransfected MCF7 cells or cells expressing MT1-MMP alone or
together with GFP-s14, or GFP-swiggle were incubated on colloidal gold-coated coverslips for 24 hours at 37°C. Cells were then fixed and
immunostained with an MT1-MMP antibody. The area of migration of at least 50 cells was measured and averaged. Representative phagokinetic
tracks generated by MCF7 cells expressing MT1-MMP and (B) GFP-s14 or (C) GFP-swiggle.
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H) or GFP-swiggle (Figure 6, panels I to P) were incu-
bated with an anti-MT1-MMP antibody on ice, and
then warmed to 37°C to restore endocytosis. In cells
expressing MT1-MMP alone (data not shown) or MT1-
MMP and GFP-s14 (Figure 6, panels A to H), the anti-
body-bound MT1-MMP originally present at the cell
surface (time zero; Figure 6, panel A) was quickly inter-
nalized at 37°C. Accumulation of vesicles containing
antibody-bound MT1-MMP was clearly observed in the
cytoplasm of the cells expressing GFP-s14 (Figure 6,
panels B, C and D), demonstrating that the MT1-MMP
antibody complex was internalized in these cells. In con-
trast, in MCF7 cells expressing MT1-MMP and GFP-
swiggle (Figure 6, panels I to P), we observed a marked
reduction of vesicles containing antibody-bound MT1-
MMP, with most of the MT1-MMP antibody complex
present at the cell surface when the cells were incubated
at 37°C (Figure 6, panels J, K and L). A low level of
internalization of antibody bound MT1-MMP com-
plexes could however be detected by 50 minutes (Figure
6, panel L) in cells expressing GFP-swiggle. Quantifica-
tion of MT1-MMP endocytosis MCF7 cells transfected
with MT1-MMP and GFP-s14 or MT1-MMP and GFP-
swiggle after 0, 10, 30 or 50 minutes at 37°C is pre-
sented in Figure 7.
Swiggle interacts with the MT1-MMP LLY
573
internalization motif
The internalisation of MT1-MMP has been shown to be
able to occur via clathrin- or caveolin-mediated path-
ways [49,53,31,32]. Because MCF7 cells do not express
detectable levels of caveolin-1 [54-58], we asked whether
GFP-swiggle was able to interfere with the clathrin-
mediated internalisation of the protease.
Clathrin-mediated endocytosis of MT1-MMP has pre-
viously been shown to involve the μ2 subunit of the
adaptor protein AP-2, which interacts with the LLY
573
motif found in the MT1-MMP ICD [31]. Therefore, the
inhibition of MT1-MMP internalization observed fol-
lowing expression of GFP-swiggle could potentially
result from a disruption of the interaction between
MT1-MMP and μ2. The first test of this hypothesis was
to ask whether the LLY
573 motif required for μ2 binding
is also required for binding by swiggle. We therefore
generated a LexA-MT1 LLY/A triple mutant, where the
LLY
573 motif in the MT1-MMP ICD was replaced by
AAA
573, and tested its interaction with AD-swiggle in
the yeast two-hybrid interaction assay. As before, we
were able to detect a strong interaction in yeast expres-
sing LexA-MT1 and AD-swiggle (Figure 8A; compare to
Figure 1B). In contrast, no interaction was found
between LexA-MT1 LLY/A and AD-swiggle (Figure 8A)
suggesting that the LLY
573 motif of MT1-MMP plays a
crucial role in the interaction between swiggle and the
MT1-MMP ICD.
If swiggle and μ2 both bind to the LLY
573 motif of
MT1-MMP, then expression of swiggle should competi-
tively inhibit the interaction between μ2 and MT1-MMP
in cells. To test this idea, MCF7 cells were transiently co-
transfected with MT1-MMP alone or with MT1-MMP
together with GFP-s14 or GFP-swiggle. Total cell lysates
were subjected to immunoprecipitation with the anti-
MT1-MMP antibody and immune complexes were
probed with anti-μ2, -MT1-MMP and -GFP antibodies.
As shown in Figure 8B, we observed a clear co-immuno-
precipitation of MT1-MMP and μ2 when the protease is
expressed alone (Figure 8B, lane 2), or in the presence of
GFP-s14 (Figure 8B, lane 3). In contrast, we were unable
to detect μ2 in complexes immunoprecipitated from
Figure 4 Expression of GFP-swiggle increases cell surface localisation of MT1-MMP. Cell surface proteins of MCF7 cells transfected with
MT1-MMP, and GFP (lane 1), GFP-TrxA (lane 2), GFP-s14 (lane 3), or GFP-swiggle (lane 4) were biotinylated and immunoprecipitated using an
anti-biotin antibody. The presence of MT1-MMP in the immunoprecipitate (top panel) and in the input lysates (bottom panel) was detected
using an anti-MT1-MMP antibody.
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(Figure 8B, lane 4), thus demonstrating that expression of
the PA inhibits the formation of a complex between the
protease and the μ2 subunit. Taken together, our data
suggest that the inhibition of MT1-MMP endocytosis
observed following expression of swiggle probably results
from the interaction of the PA with the LLY
573 motif of
the MT1-MMP ICD, thus disrupting the interaction of
the MT1-MMP ICD with the μ2 subunit. Our results
thus suggest a potential mechanism for the amplification
of the effects of MT1-MMP on cell migration by GFP-
swiggle. They also demonstrate that swiggle binding to
Figure 5 GFP-swiggle increases MT1-MMP-mediated Texas Red-gelatin degradation. Example of Texas-Red gelatin degradation (white
dotted line) by MCF7 cells expressing MT1-MMP and (A) GFP-s14 or (B) GFP-swiggle after 16 hours incubation at 37°C. GFP-s14 or GFP-swiggle
(green) and MT1-MMP (purple) expression were detected by immunofluorescence. Bar = 20 μm (C) Quantification of the area of migration of at
least 50 untransfected MCF7 cells or 50 cells transfected with GFP-s14, GFP-swiggle, MT1-MMP, MT1-MMP + GFP-s14, MT1-MMP + GFP-swiggle,
MT1-MMP E240A, MT1-MMP E240A + GFP-s14, MT1-MMP E240A + GFP-swiggle, MT1-MMP ΔICD, MT1-MMP ΔICD + GFP-s14 or MT1-MMP ΔICD +
GFP-swiggle. Data represent average area of migration ± s.e.m..
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affecting communication between the ICD and the
machinery required for cell migration.
Discussion
In this study, we have described the isolation and char-
acterisation of a PA, called swiggle, which binds to the
ICD of the membrane-bound matrix metalloproteinase,
MT1-MMP. Our results have several implications for
PA technology. Firstly, we have demonstrated that PAs
can be successfully obtained against small intracellular
domains of transmembrane proteins. Although short
peptides have previously been used in yeast two hybrid
interaction assays, for example to map interaction
domains, the 21 amino acid MT1-MMP ICD bait is
approximately three times smaller than the previous
Figure 6 GFP-swiggle inhibits internalization of MT1-MMP. MCF7 cells, transiently co-transfected with MT1-MMP and either GFP-s14 (A-H) or
GFP-swiggle (I-P) were incubated with an anti-MT1-MMP antibody for 2 hours at 4°C. Cells were then washed and fixed immediately with
paraformaldehyde (A, E, I and M) or warmed to 37°C for 10 (B, F, J and N), 30 (C, G, K and O) or 50 (D, H, L and P) minutes before fixation. MT1-
MMP is shown in panels A to D and I to L. GFP-s14 is shown in panels E to H and GFP-swiggle in panels M to P. Bar, 5 μm.
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C-terminal portion of the HPV-16 E7 protein [6]. Our
bait is also more than six times smaller than the only
other published ICD used in a PA screen, the 133
amino acid ICD of the EGF receptor [7]. Given the
dearth of tools to directly study the biology of the MT1-
MMP ICD, which could be attributed to its small size,
this study raises the possibility that PA technology could
be used to generate tools to study the biology of other
small intracellular domains, such as integrins, that were
previously difficult to study.
PAs have traditionally been found to produce inhibitory
phenotypes by blocking certain functions of their target
proteins [10,3,11,5,8,13,9]. For example, PAs that inter-
acted with the human papilloma virus (HPV) E6 oncopro-
tein could block E6-mediated degradation of p53, resulting
in increased p53 protein levels, growth inhibition and
apoptosis in HPV-positive HPV16 cells [5]. In contrast, we
f o u n dt h a te x p r e s s i o no fG F P - s w i g g l er e s u l t e di na n
increase in both MT1-MMP-mediated TR-gelatin degra-
dation and cell migration. Furthermore, GFP-swiggle
appeared to affect the amount of MT1-MMP at the cell
surface. This increased gain of function migratory pheno-
type caused by GFP-swiggle is unique, although it is con-
sistent with the original prediction for the mechanism of
PA function [1] in that it appears to result from a loss of
function, namely reduction of the rate of endocytosis of
MT1-MMP. Although a previous study has described a
PA that stimulates its target protein, calcineurin, this PA
was identified from an anti-proliferative phenotypic
screen, rather than a yeast-two hybrid screen with a
defined bait [59]. The phenotype of this PA is also the
opposite of swiggle, with a gain of function of its target
resulting in a loss of function phenotype. Together, these
studies thus demonstrate the broad applicability of PA
technology to the dissection of cell biology.
The increase in MT1-MMP mediated cell migration
and TR-gelatin degradation mediated by GFP-swiggle
most probably results from the inhibition of endocytosis
leading to increased levels of the protease at the cell
surface. However, ICD mutants used in other studies
that resulted in increased levels of MT1-MMP protein
at the cell surface did not cause any effect on cell migra-
tion/invasion [30,31,33]. For example, over-expression of
wild type MT1-MMP leads to increased cell migration
and invasion, but truncations of the ICD including the
LLY
573 residues, or removal of the whole of the ICD
prevented these effects [30,31,33]. This appears paradox-
ical as truncations that decrease the rate of MT1-MMP
internalization should result in more MT1-MMP being
present at the cell surface, and hence more proteolytic/
migratory activity. One possible explanation for this
observation is that the LLY
573 motif of the MT1-MMP
ICD is required both for clathrin-mediated internalisa-
tion and MT1-MMP-mediated cell migration. However,
no tools previously existed to test this idea. Our results
now show that the expression of GFP-swiggle reduces
the rate of internalization of MT1-MMP and results in
an increased amount of MT1-MMP at the cell surface,
mimicking this aspect of LLY
573 mutation. But unlike
the ICD LLY
573 mutation, GFP-swiggle also allows cell
migration to proceed.
Figure 7 Quantification of MT1-MMP endocytosis in MCF7 cells transfected with MT1-MMP and GFP-s14 or GFP-swiggle.M C F 7c e l l s
transiently co-transfected with MT1-MMP and either GFP-s14 or GFP-swiggle were incubated with an anti-MT1-MMP antibody for 2 hours at 4°C.
Cells were fixed immediately (0 min) or after 10, 30 or 50 minutes at 37°C. Data represent the average of the total fluorescence intensity of
endosomes per cell ± s.e.m..
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[30,31,33], is that the majority of the assays that were used
were only sensitive to over-expressed levels of MT1-
MMP. While this may reflect the pathological situation in
cancer cells, further work is needed to assess whether
GFP-swiggle can perturb other functions of MT1-MMP in
normal cells through the development of assays that are
sensitive to endogenous levels of MT1-MMP.
Conclusions
In summary, we have identified and characterized a PA
that, when expressed in mammalian cells, can inhibit
the clathrin-mediated internalisation of MT1-MMP by
interacting with the normal function of the ICD of the
protease. In addition to laying the ground-work for the
study of the mechanism of endocytic recycling of trans-
membrane MMPs, this PA should be a useful tool in
further studies of MT1-MMP in the existing wide range
of biological and disease models.
Methods
All chemicals were AnalaR grade and were purchased
from Sigma Aldrich Chemical Co. (Poole, UK) unless
indicated otherwise.
Figure 8 Swiggle interacts with the LLY
573 motif of the MT1-MMP ICD. (A) EGY48 cells expressing LexA-DBD, LexA-MT1, the LexA-MT1 LLY/
A mutant or LexA-Cdk4 were mated with EGY42 cells expressing AD-swiggle, AD-s14 or AD-CyclinD1 and plated onto selective media. (B) Cell
lysates prepared from MCF7 cells expressing MT1-MMP alone (lanes 1 and 2) or together with GFP-s14 (lane 3) or GFP-swiggle (lane 4) were
subjected to immunoprecipitation in the presence (lanes 2, 3 and 4) or the absence (lane 1) of an anti-MT1-MMP pAb The presence of μ2 and
MT1-MMP in the immunocomplexes was monitored by Western blotting. The expression level of GFP-s14, GFP-swiggle or μ2 in the input lysates
was analysed by Western blot.
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Oligonucleotides coding for a PGGG linker followed by
MT1-MMP, MT2-MMP, MT3-MMP, or MT5-MMP
intracellular domain (ICD) were annealed and cloned
downstream of the LexA DNA binding domain (DBD)
in pEG202 (Origene, Rockville, USA) to generate LexA-
MT1, -MT2, -MT3 and -MT5. The MT1-MMP ICD
LLY/A mutant in pEG202 was created by site-directed
mutagenesis (Stratagene, La Jolla, CA, USA). Swiggle,
and s14, all in pJG4-5 (Origene), were amplified by PCR
and subcloned into pIRES2eGFP (BD Clontech, UK).
Swiggle and s14 were excised from the above constructs
and subcloned into BretGFP-C1 (PerkinElmer, Boston,
M A ,U S A ) .T r x A ,e x c i s e df r o mp J M - 1( g i f tf r o mR .
Brent, Berkeley, USA) was subcloned into BretGFP-C2.
N-terminally His6-tagged swiggle was generated by
cloning swiggle into pET32a (Merck Biosciences Ltd.,
Nottingham, UK).
Yeast two-hybrid screen
The peptide aptamer (PA) library containing a B42 AD
fusion to 1 × 10
6 different PAs was constructed as
described in [45] and transformed into the reporter S.
cerevisiae strain EGY48 (MATa leu2::LexA 6op-LEU2
his3 trp1 ura3) [60]. These cells were mated with
EGY42 cells (MATa leu2 his3 trp1 ura3)[ 1 0 ] )c a r r y i n g
LexA-MT1. The two-hybrid mating screen was per-
formed essentially as described by [60]. Interactors,
selected on Ura
-His
-Trp
-Leu
-/X-Gal, Gal, Raff plates
after four days at 30°C, were picked and the plasmids
rescued into E. coli KC8 cells. The plasmids were trans-
formed back into EGY48 to confirm interaction with
LexA-MT1 in EGY42 using an interaction-mating
matrix. LexA-Cdk4 and AR cDNAs were kindly pro-
vided by P. Hinds and M. Lu (Harvard Medical School,
USA). AD-CyclinD1 cDNA was from R. Brent (Molecu-
lar Sciences Institute, Berkeley CA, USA).
Isolation of mutants of swiggle by PCR mutagenesis of
the swiggle peptide insert
PCR mutagenesis of the swiggle peptide insert was per-
formed as previously described [61] except for the follow-
ing alterations. Mutated swiggle sequences were ligated
into RsrII-cut pJM-1 vector and were transformed into
XL-10 gold E. coli cells (Invitrogen Ltd., Paisley, UK).
Plasmid DNA was isolated using Qiagen midi-prep DNA
extraction kit (Qiagen, Crawley, UK), and transformed (1
μg) into EGY48 containing LexA-MT1 and pJK103 [61].
Positive (blue) and negative (white) interactors were
selected on Ura
-His
-Trp
-Leu
-/X-Gal, Gal, Raff plates for
four days, picked and the plasmids rescued into E. coli
KC8 cells. Plasmids were transformed back into EGY48
to confirm interaction with LexA-MT1 in EGY42 using
an interaction-mating matrix.
Cell culture and transfections
All cell culture reagents were purchased from Invitrogen
Ltd. unless indicated. MCF7 cells, purchased from
ECACC (Salisbury, UK), were maintained in DMEM,
supplemented with 10% (vol/vol) fetal calf serum (FCS,
Hyclone Laboratories, UT, USA) and 2 mM L-glutamine
at 37°C in 5% CO2 atmosphere. Transfections were per-
formed using FuGENE-6 reagent (Roche Diagnostics,
Lewes, UK) according to manufacturer’s instructions.
Immunoprecipitation and western blotting
MCF7 cells were transfected for 48 hours with either
0.4 μg GFP-swiggle and 0.6 μg MT1-MMP constructs,
or 0.4 μgG F P - T r x Aa n d0 . 6μg MT1-MMP in 6-well
plates. After 2 washes with ice-cold PBS, cells were
lysed for 15 minutes on ice under rocking conditions
in 200 μl of lysis buffer (50 mM Tris-HCl, pH 7.4,
100 mM NaCl, 2 mM EDTA, 1% Triton X-100, 60 mM
octyl-D-glucoside) supplemented with complete protease
inhibitor cocktail (Roche Molecular Biochemical, Hert-
fordshire, UK), sonicated (80 Volts for 10 seconds,
Sonics and Material Inc., Suffolk, UK) and centrifugated
(10 minutes at 15000 g at 4°C). An aliquot (10%) of the
protein extract was kept and analysed by Western blot
(input lysate). The remaining protein extract was incu-
bated for 2 hours at 4°C with an anti-GFP rabbit poly-
clonal serum (dilution 1/2200). Protein G sepharose
beads (20 μl of slurry) were then added and the mixture
rotated for a further 2 hours at 4°C. Beads were washed
four times with 1 × PBS, once with PBS diluted 5 times
in distilled water and finally were resuspended in
Laemmli sample buffer (LSB). Immunoprecipitates and
input lysates were boiled for 5 minutes, resolved on 12%
SDS-polyacrylamide gels, and electrotransferred onto
PVDF membrane (Millipore, Watford, UK). Western
blots were carried out as previously described [45]. Rab-
bit anti-GFP serum (Abcam, Cambridge, UK) was used
at a 1:2000 dilution. The anti-MT1-MMP sheep N175
pAb, directed against the entire extracellular of the
protease [49,50], was used at 10 μg/ml.
Cell surface biotinylation of proteins
Cell surface biotinylation was carried out as previously
described [49], except for the following alterations.
MCF7 cells (1 × 10
5) were transfected with 0.4 μg GFP-
swiggle and 0.6 μg MT1-MMP, 0.4 μgG F P - T r x Aa n d
0.6 μgM T 1 - M M P ,0 . 4μgG F P - s 1 4a n d0 . 6μgM T 1 -
MMP, or 0.4 μgG F Pa n d0 . 6μg MT1-MMP in 6-well
plates. PBS buffer was substituted for Soerensen buffer
(SBS). Cells were incubated for 30 minutes in ice-cold
PBS containing 0.5 mg/ml of NHS-SS-Biotin (Pierce
Biochemical, Rockford, USA) and lyzed for 15 minutes
at 4°C in 200 μl ice-cold RIPA buffer containing pro-
tease inhibitor III cocktail (Calbiochem Biochemical,
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gation (16000 g for 5 minutes at 4°C) and incubation
with protein A/G plus-agarose beads (25 μl; Santa Cruz
Biotechnology, Santa Cruz, USA) for 1 hour at 4°C. An
aliquot of the whole cell lysate (20 μl; input lysate) was
kept for western blot analysis. Anti-biotin mAb (12 μg;
Jackson Immunoresearch Ltd., Soham, UK) and Protein
A / GP l u sa g a r o s eb e a d s( 3 0μl) were then added to the
extract and incubated for 1 hour at 4°C under constant
rotation. Beads were washed five times with ice-cold
RIPA buffer, resuspended in LSB and processed for
western blotting as previously described.
Immunofluorescence microscopy
Cells seeded on glass coverslips were washed in PBS,
fixed at room temperature (RT) in 4% (wt/vol) parafor-
maldehyde (PFA, BDH, Poole, UK) for 5 minutes and
washed twice with PBS. For permeabilized cells, cover-
slips were incubated in 0.2% Triton-X100 in PBS for 5
m i n u t e sa tR T ,a n dw a s h e dt h r e et i m e si n2×P B S .
Cells were blocked for 30 minutes at RT with PBS con-
taining 10% FCS and 10 μg/ml BSA, and then incubated
with the anti-MT1-MMP sheep pAb (10 μg/ml) for 16
hours at 4°C in PBS containing 10 μg/ml BSA. After 3
washes in PBS, cells were incubated for 1 hour at RT
with fluorescently-conjugated secondary antibody (Jack-
son Immunoresearch Ltd.) in PBS and according to the
manufacturer’s instructions. Coverslips were washed
repeatedly in PBS, and mounted onto glass slides using
Vectashield containing diamidino-2-phenylindole (DAPI,
Vector Laboratories, Burlingame, USA). Images of fluor-
escently labelled cells were collected using a Zeiss
LSM510 Metaconfocal microscope in a single focal
plane (Carl Zeiss Ltd., Welwyn Garden City, UK).
Texas Red-labelled Gelatin Degradation Assay
Texas Red labelled-gelatin was coated, as previously
described by [50] on the glass surface of 8 well Labtek
culture slides (Becton Dickinson Labware, USA) and
incubated for 2 hours at 37°C in DMEM containing 10%
FCS. Untransfected MCF7 cells (5 × 10
4 per well) were
then seeded on the fluorescent gelatin and incubated for
16 hours at 37°C. Cell transfections were carried out
using FuGENE-6 (0.75 μl) and 250 ng of DNA (ratio
used). Cells were then washed in warmed PBS, fixed
with 4% (w/v) PFA in PBS and then processed immuno-
fluorescence microscopy using the anti-MT1-MMP
sheep pAb as described above. A Cy5 conjugated don-
key anti-sheep secondary antibody (1:200 dilution) was
used (Jackson Immunoresearch).
For each condition, pictures of at least 50 cells in a sin-
gle focal plane were taken with a Zeiss 510 Meta confocal
microscope. The area of TR-gelatin degradation was then
measured with Zeiss AIM software (version 3.2).
Phagokinetic track colloidal gold cell migration assay
The phagokinetic track colloidal gold cell migration
assay was performed as described previously [18]. Col-
loidal gold-coated coverslips were placed in a 12-well
plate, and transfected MCF7 cells were seeded at 2 ×
10
3 cells per well. After 24 hours incubation at 37°C,
cells were fixed as previously described and phagokinetic
tracks were visualized using bright field illumination
with a Zeiss 510 Meta confocal microscope. The area of
migration for at least 50 transfected cells was measured
with Zeiss AIM software and averaged.
MT1-MMP antibody internalization assay
MCF7 cells, co-transfected with GFP-swiggle (0.4 μg)
and MT1-MMP (0.6 μg), or GFP-s14 (0.4 μg) and MT1-
MMP (0.6 μg), were seeded on glass coverslips in 6-well
plates. After 48 hours transfection, cells were washed
twice with ice-cold PBS and incubated with the affinity
purified N175 anti-MT1-MMP sheep pAb (5 μg/ml) at
4°C for 2 hours. Coverslips were then washed twice with
ice-cold PBS to remove unbound antibody and fixed
immediately (zero minute timepoint) in 4% PFA for 10
minutes or placed at 37°C for 10, 30 and 50 minutes in
prewarmed media before fixation. Cells were permeabi-
lized and processed for immuno-fluorescence micro-
scopy as previously described. Endocytosis was
quantified by measuring the fluorescence intensity of all
endocytic vesicles per cell using Metamorph imaging
software version 6.1 (Molecular Devices Ltd., Woking-
ham, UK) as previously described by [62]. At least 5
cells were used for time 0 and 15 cells for the other
time points.
Abbreviations
PA: peptide aptamer; ECM: Extra-cellular matrix; MT1-MMP: membrane-type I
matrix metalloproteinase; ICD: intracellular domain; DBD: DNA-binding
domain; AD: activation domain.
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